Sanofi (SNY) To Go Ex-Dividend on May 9th

Sanofi (NASDAQ:SNY) declared an annual dividend on Tuesday, March 26th, Zacks reports. Investors of record on Friday, May 10th will be paid a dividend of 1.478 per share on Thursday, June 6th. This represents a yield of 2.98%. The ex-dividend date of this dividend is Thursday, May 9th. This is an increase from Sanofi’s previous annual dividend of $1.38.

Sanofi has increased its dividend payment by an average of 3.8% per year over the last three years and has raised its dividend annually for the last 1 consecutive years. Sanofi has a payout ratio of 40.1% meaning its dividend is sufficiently covered by earnings. Research analysts expect Sanofi to earn $4.72 per share next year, which means the company should continue to be able to cover its $1.90 annual dividend with an expected future payout ratio of 40.3%.

Sanofi Stock Down 0.4 %

Shares of NASDAQ:SNY opened at $49.54 on Thursday. Sanofi has a 12 month low of $42.63 and a 12 month high of $57.82. The company has a current ratio of 1.27, a quick ratio of 0.87 and a debt-to-equity ratio of 0.19. The company has a 50-day moving average price of $48.19 and a 200 day moving average price of $49.42. The company has a market cap of $125.32 billion, a price-to-earnings ratio of 20.99, a PEG ratio of 1.84 and a beta of 0.61.

Sanofi (NASDAQ:SNY) last released its quarterly earnings results on Thursday, February 1st. The company reported $0.89 EPS for the quarter, missing analysts’ consensus estimates of $0.94 by ($0.05). Sanofi had a return on equity of 27.47% and a net margin of 12.56%. The firm had revenue of $11.76 billion for the quarter, compared to analysts’ expectations of $13.02 billion. As a group, equities research analysts predict that Sanofi will post 4.19 earnings per share for the current year.

Wall Street Analyst Weigh In

SNY has been the topic of several recent analyst reports. Morgan Stanley started coverage on Sanofi in a report on Tuesday, January 23rd. They issued an “equal weight” rating and a $55.00 price target on the stock. TheStreet cut shares of Sanofi from a “b” rating to a “c” rating in a report on Friday, February 9th. JPMorgan Chase & Co. downgraded shares of Sanofi from an “overweight” rating to a “neutral” rating in a research note on Tuesday, December 5th. Finally, StockNews.com downgraded Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 27th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $55.00.

Institutional Trading of Sanofi

Several hedge funds have recently modified their holdings of SNY. SRS Capital Advisors Inc. raised its stake in shares of Sanofi by 289.1% during the 1st quarter. SRS Capital Advisors Inc. now owns 463 shares of the company’s stock worth $25,000 after acquiring an additional 344 shares in the last quarter. Fairfield Bush & CO. acquired a new position in shares of Sanofi during the first quarter worth $26,000. Eagle Bay Advisors LLC purchased a new stake in shares of Sanofi during the 2nd quarter valued at $28,000. O Dell Group LLC acquired a new stake in shares of Sanofi in the 4th quarter worth $40,000. Finally, First Manhattan Co. grew its stake in Sanofi by 42.7% during the 4th quarter. First Manhattan Co. now owns 999 shares of the company’s stock worth $48,000 after buying an additional 299 shares during the last quarter. 10.04% of the stock is owned by hedge funds and other institutional investors.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.